SPCG-9

An open pilot study evaluating intermittent androgen suppression in patients with advanced prostate cancer

Etiam porta sem malesuada magna mollis euismod. Maecenas sed diam eget risus varius blandit sit amet non magna. Nullam quis risus eget urna mollis ornare vel eu leo. Donec id elit non mi porta gravida at eget metus. Nullam quis risus eget urna mollis ornare vel eu leo.

Finished

SPCG-9 info

Principal investigator

Per-Anders Abrahamsson. Knud V. Pedersen

Contact details

Patients

T3-4 ,Nx,M0 / T1-4,Nx,M1. PSA ≥ 20

Treatment

GnRH (plus flare protection) for 9 months. Intermittent treatment, if PSA-response ≤ 4. Treatment pauses until PSA > 20

Inclusion period

Dec. 1998 – March 2000

Number of patients

142, Data cut off: may 2002

Sponsor

AstraZeneca, Ferring and Schering-Plough

An open pilot study evaluating intermittent androgen suppression in patients with advanced prostate cancer

SPCG-9 info

More trials

SPCG 19/ Get-Randomized- Prostate (Grand-P): A randomized, multi-center trial of immediate curative therapy compared with standard conservative treatment in older men aged ≥ 75 years with non-metastatic, high-risk prostate cancer

Prostate Cancer Active Surveillance Trigger Trial (PCASTT)

No information available

Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial

A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation ± Docetaxel for Non-metastastic Prostate Cancer Patients with a Rising PSA

A Randomized phase III trial of six cycles of docetaxel versus surveillance plus hormonal treatment after radical radiotherapy in patients with intermediate or high-risk prostate cancer (SPCG-13 AdRad)

An open randomised phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 or margin positive pT2

Randomised trial comparing radical prostatectomy versus radiotherapy plus protocol on follow-up of non-randomised patients with localised prostate cancer

Antiandrogen followed by TAB on biochemical progression versus TAB

Institution of second-line Estracyt therapy at an increase in PSA values for metastatic prostate cancer

Post-treatment Prostatic Biopsies after Antiandrogen treatment with or without Radiotherapy

Randomized trial of locally advanced prostate cancer. Antiandrogen treatment with or without radiotherapy

A randomized, double-blind, parallel-group trial comparing Casodex 150 mg once daily with placebo in patients with non-metastatic prostate cancer

High-dose Polyestradiol Phosphate versus Total Androgen Blockade

Expectation or radical prostatectomy on early prostate cancer

Cancelled trial due to Socialstyrelsen in Sweden

Orchiectomy plus placebo versus orchiectomy plus cyproteronacetat

Comparison of Estramustine Phosphate to Stilbestrol in the treatment of G3 M Prostatic